Abstract: An improved process for inactivating an extracellular lipid enveloped virus or an intracellular lipid enveloped virus which may be present in an extracorporeal composition containing red blood cells by subjecting the composition to a virucidally effective amount of a phthalocyanine compound and red light of a fluence rate of at least above about 5 mW/cm.sup.2. Quite contrary to what would have been expected, it has been found that higher light fluence rates are, in fact, more protective of red blood cells than are lower light fluence rates.

Abstract: This invention relates to methods of removing undesired antibodies from blood-derived compositions containing both the antibodies and coagulation factors, such that the coagulation factors are substantially retained in the composition. The undesired antibodies may be blood group antibodies. This invention also relates to compositions in which undesired antibodies have been removed and desired coagulation factors are retained. This invention further relates to methods of inactivating virus and removing undesired antibodies from blood-derived compositions containing virus, antibodies and coagulation factors without removing coagulation factors therefrom, and to the resulting compositions.

Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.

Abstract: A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method of treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.

Abstract: The present invention concerns the product produced by inactivating extracellular lipid enveloped pathogenic virus or intracellular pathogenic virus in a composition containing >1.times.10.sup.9 cells/ml and said virus without incurring substantial disruption or inactivation of such cells, the inactivation process comprising contacting the composition with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer, thereby substantially to inactivate the virus with retention of cell functionality, greater than 80%. The present invention also concerns the product produced by inactivating virus in a biological composition without incurring substantial disruption or inactivation thereof, the inactivation process comprising contacting said composition with a virucidally effective amount of at least one photoreactive compound, light, and a quencher thereby to inactivate said virus while retaining functionality of said substance.

Abstract: The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having .gtoreq.1.times.10.sup.9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of .gtoreq.630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10.sup.4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of .gtoreq.1.times.10.sup.9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.

Abstract: A process of inactivating infectious viruses in a cell-containing or a protein-containing composition containing such viruses, comprising contacting such composition with an effective amount of at least one aryl diol epoxide of the formula ##STR1## in which X is an aromatic ring system having from 3 to 6 used rings,for a sufficient period of time substantially to inactivate said viruses without incurring substantial disruption or inactivation of cells or without incurring substantial protein denaturation.

Abstract: A method of removing lipid soluble chemicals from a biological material containing the lipid soluble chemicals comprising bringing the biological material containing the lipid soluble chemicals into contact with an effective amount of an organic alcohol whose solubility in an aqueous solution at the temperature of use is .ltoreq.0.6% and/or a halogenated hydrocarbon having more than one type of halogen, agitating the resultant mixture and achieving a phase separation of the biological material and the organic alcohol and/or halogenated hydrocarbon. The method is particularly useful for producing relatively virus free physiologically acceptable plasma.

Abstract: There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatty acid or a soluble ester, alcohol or a salt thereof for a sufficient period of time to inactivate virus contained therein.

Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.

Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.

Abstract: There is disclosed a process for obtaining a protein-containing composition which is substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said protein-containing composition with an effective amount of oleic acid, its ester or alkali or alkaline earth metal salt for a sufficient period of time to inactivate virus contained therein.

Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.